Supplemental Selenium and Vitamin E and Pulmonary Function

Overview

To test whether supplementation with selenium and/or vitamin E affects pulmonary function.

Full Title of Study: “The Respiratory Ancillary Study (RAS) to SELECT”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 2010

Detailed Description

BACKGROUND: There is compelling evidence from observational epidemiologic studies that intakes of nutrients with antioxidant properties are associated with reduced risks of chronic obstructive disease (COPD) and increased lung function. This study is ancillary to the multisite Selenium and Vitamin E Cancer Prevention Trial (SELECT), a 4-arm placebo-controlled, double-blinded randomized trial in 35,000 men testing whether daily supplementation with vitamin E (400mg alpha-tocopherol), selenium (200 micrograms selenomethionine) or both vitamin E and selenium can prevent prostate cancer. DESIGN NARRATIVE: This study is ancillary to the multisite Selenium and Vitamin E Cancer Prevention Trial (SELECT), a 4-arm placebo-controlled, double-blinded randomized trial in 35,000 men testing whether daily supplementation with vitamin E (400mg alpha-tocopherol), selenium (200 micrograms selenomethionine) or both vitamin E and selenium can prevent prostate cancer. A total of 3,000 SELECT participants will be enrolled for this respiratory ancillary study, and data collection will be extended to include pulmonary function, respiratory disease, and respiratory symptoms. Biological measures of nutrient exposure (serum vitamin E and selenium) and plasma lipids (total and high-density lipoprotein cholesterol) will be collected on all participants and oxidant burden (urinary F2-isoprostane) on a sub sample of heavy smokers and men with COPD. The primary outcome will be change over about 36 months in forced expiratory volume in the first second (FEV1). FEV1 is a valid and reliable measure of respiratory function that strongly predicts COPD and mortality. Extensive data on diet and dietary supplement use are being collected by the SELECT parent study. All specific aims examine pre-specified contrasts between the 4 arms of the SELECT randomized trial. The underlying hypothesis is that supplements will reduce the age related decline in FEV1 and thus at the 3-year follow-up FEV1, which will be tested in longitudinal and cross-sectional models. A secondary aim considers whether the effect of supplementation is greater among smokers (high burden of exogenous oxidants) who, by purposive selection of the study sites, will comprise about 25% of the sample.

Interventions

  • Dietary Supplement: Vitamin E
    • vitamin E (400 IU/day all rac-α-tocopheryl acetate)
  • Dietary Supplement: Selenium
    • selenium (200 μg/d L-selenomethionine)
  • Dietary Supplement: Vitamin E placebo
    • placebo
  • Dietary Supplement: Selenium placebo
    • placebo

Arms, Groups and Cohorts

  • Experimental: Vitamin E and selenium placebo
    • Vitamin E alone
  • Experimental: Selenium and vitamin E placebo
    • Selenium alone
  • Experimental: Vitamin E and selenium
    • Vitamin E and selenium combined
  • Placebo Comparator: vitamin E Placebo and Selenium placebo
    • Double placebo

Clinical Trial Outcome Measures

Primary Measures

  • Change in pulmonary function over time by arm of study
    • Time Frame: Outcome is assessed at annual and bi-annual study visits, during in-person visit of participant to the study site. Over a period of about 36 to 48 months, participants are assessed between 3 and 4 times

Participating in This Clinical Trial

Eligibility criteria:

  • age ≥ 55 y (≥ 50 y in African-Americans) – serum prostate-specific antigen ≤ 4ng/mL – no clinical evidence of prostate cancer Exclusion criteria:

  • Off both SELECT supplements

Gender Eligibility: Male

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Cornell University
  • Collaborator
    • National Heart, Lung, and Blood Institute (NHLBI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Patricia A. Cassano, PhD, Principal Investigator, Cornell University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.